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SnailTransforming growth factor beta (TGFβ) is believed to play a dual role in prostate cancer. Molecular mechanism
by which TGFβ1 suppresses early prostate tumor growth and induces epithelial-to-mesenchymal transition
(EMT) in advanced stages is not known. We determined if P21-activated kinase1 (Pak1), which mediates cyto-
skeletal remodeling is necessary for the TGFβ1 induced prostate cancer EMT. Effects of TGFβ1 on control prostate
cancer PC3 and DU145 cells and those with IPA 3 and siRNA mediated Pak1 inhibition were tested for prostate
tumor xenograft in vivo and EMT in vitro. TGFβ1 inhibited PC3 tumor xenograft growth via activation of P38-
MAPK and caspase-3, 9. Long-term stimulationwith TGFβ1 induced PC3 and DU145 cell scattering and increased
expression of EMT markers such as Snail and N-cadherin through tumor necrosis factor receptor-associated
factor-6 (TRAF6)-mediated activation of Rac1/Pak1 pathway. Selective inhibition of Pak1 using IPA 3 or knock-
down using siRNAboth signiﬁcantly inhibited TGFβ1-induced prostate cancer cell EMT and expression ofmesen-
chymal markers. Our study demonstrated that TGFβ1 induces apoptosis and EMT in prostate cancer cells via
activation of P38-MAPK and Rac1/Pak1 respectively. Our results reveal the potential therapeutic beneﬁts of
targeting TGFβ1-Pak1 pathway for advanced-stage prostate cancer.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer is one of themost common cancers and is the second
leading cause of cancer-related death among men in the United States
[22,43]. Metastatic prostate cancer is very difﬁcult to treat and is the
main cause of death among prostate cancer patients [12]. The mecha-
nism by which prostate cancer cells metastasize to distant organs is
not clearly understood. One of the most accepted theories of metastasis
is that tumor cells will undergo epithelial to mesenchymal transition
(EMT) characterized by induction of mesenchymal markers accompa-
nied with loss of epithelial markers [31,48].
Transforming growth factor beta (TGFβ) is a cytokine that plays a
fundamental role in various cellular functions. However, deregulation
of TGFβ pathway can lead to various pathological conditions, including
cancer [2,23,34]. Although studies have demonstrated the tumor
suppressive role of TGFβ1 during the early stages of hyperplasia and
tumor development, it switches to a tumor promoter during the
advanced metastatic stages of cancer [14,26,34,52]. TGFβ1, the most
ubiquitous and best characterized isoform promotes tumor progressiond Experimental Therapeutics,
—Georgia Regents University,
; fax: +1 706 721 3994.and metastasis in advanced cancers utilizing different pathways;
both canonical Smad-dependent pathways and non-canonical Smad-
independent pathways [27,29,42]. One of the best characterized cellular
modiﬁcations during EMT in any tissues is the increased expression of
mesenchymal cell-surface markers such as N-cadherin and Snail [9,44]
and loss of epithelial markers such as E-cadherin and cytokeratins
[9,19]. Thus, EMT is a pre-requisite for the advanced stage cancer cells
to gain the invasive characteristics. Whereas TGFβ1 activity is well
known to be associated with EMT [17,28], the mediators of TGFβ1-
induced EMT are still to be identiﬁed.
P21 activated kinases (Paks) are the major downstream effectors of
small GTPases Rac and cdc42, which are involved in the actin-based
cytoskeletal remodeling [36,37]. We have previously shown that the
pathway involving 14-3-3 adaptor proteins, Rac and Pak is important
for both physiological responses to growth factors in normal cells [45]
and in the promotion of invasion in prostate cancer cells [10]. More
recently, we demonstrated that group-I Paks such as Pak1, although
not at all expressed in normal prostatic epithelial cells, is highly
expressed in advanced prostate cancer patient samples and that
modulation of Pak1 expression and activity in prostate cancer cells is di-
rectly linked to the changes in its tumorigenic and invasive potential
[11,40,50]. Intriguingly, we also observed an unexpected correlation
between Pak1 activity and TGFβ1 expression in prostate cancer cells.
Until today, the role of Pak1 in TGFβ-induced non-canonical signaling
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Pak1 is only expressed in tumor, but not in normal prostatic epithelial
cells.
In the current study, we focused on characterizing the link between
TGFβ1-mediated EMT in prostate cancer cells with modulation of Pak1
activity. Our results demonstrate that although TGFβ1 induces apopto-
sis and tumor regression, it also stimulates Rac1 and Pak1 activities in
prostate cancer cells inducing cytoskeletal remodeling, expression of
mesenchymal markers in the promotion of EMT, enhanced cell motility
and invasion. TGFβ1-induced Pak1 activation was independent of
Smad2-mediated canonical pathway and was dependent on TRAF6-
mediated non-canonical pathway. Our study also is the ﬁrst one to
show that targeting Pak1 using IPA 3 can inhibit TGFβ1-induced pros-
tate cancer EMT and invasion.
2. Materials and methods
2.1. Reagents, cell lines and antibodies
Metastatic (androgen independent) prostate cancer cell lines (PC3
and DU145) were obtained from ATCC (Manassas, VA) and main-
tained in DMEM-High Glucose (Hyclone, Logan, UT) with 10% FBS,
100 units/ml penicillin and 100 μg/ml streptomycin in 5% CO2Fig. 1. TGFβ1 overexpression results in the growth inhibition of prostate tumor xenografts. A. Fi
bearing either Ad-GFP or Ad-TGFβ1 overexpression. B. Representative images of xenograft tumo
bodyweight on the date of tumor collection. D. Pictures showing TUNEL staining (green), DAPI
taken from either control or TGFβ1 overexpressing tumors (n=6). E.Western blot images of c
p-p38 MAPK, cleaved caspase 3, cleaved caspase 9, p-PAK1, and total PAK1 normalized to β-ac
expression normalized toβ-actin (right) (n=4). F. Bar graphs representing optical densitometr
sions inprostate tumor xenografts normalized toβ-actin (n=3). G.Western blot image of Snail
densitometry measurements of Snail expression (right) normalized to β-actin (n= 3).*p b 0.0humidiﬁed atmosphere at 37 °C. Primary antibodies against p-
Pak1/2, total Pak1, p-Smad2/3, total Smad2/3, E-cadherin, N-
cadherin, Vimentin, Keratin8/18, Snail, Slug, cleaved caspases 9 and
3, TGFβ1, TRAF6 and p-P38-MAPK were purchased from Cell Signal-
ing (Boston, MA). Primary antibody against Rac1 and β-actin were
purchased from Sigma-Aldrich (St Louis, MO). Anti-mouse and
anti-rabbit HRP conjugated secondary antibodies were purchased
from Bio-Rad (Hercules, CA). Selective Pak1 inhibitor (IPA 3) was
purchased from Tocris bioscience (Minneapolis, MN). SiPak1 and
control siRNAs were purchased from Cell Signaling (Boston, MA).
Rh-TGFβ1 was purchased from R&D systems (Minneapolis, MN).
SiTRAF6, SiSmad2 and AlexaFluor-labeled Phalloidin were pur-
chased from Life technologies (Carlsbad, CA).2.2. RNA interference
Fifty percent conﬂuent PC3 and DU145 cells were transfected with
either 100 nm of control, Pak1, TRAF6 or Smad2 siRNA using lipofecta-
mine 2000 according to the manufacturer's protocol (Life technologies,
Carlsbad, CA). Cells were transfected for 48 h (for SiPak1) or 72 h (for
SiSmad2 and SiTRAF6) and then subjected to treatment with TGFβ1
(5 ng/ml) or no treatment for 24 h.gure showing tumor volume (left) andweight (right) analysis of the PC3 tumor xenografts
r in both control and TGFβ1 overexpression groups (n=6) C. Bar graph representingmice
(blue) and bar graph indicating prostate cancer cell apoptosis in tumor xenograft sections
ontrol and Ad-TGFβ1 expressing PC3 tumor xenograft lysates showing expression levels of
tin (left) and bar graph representing optical densitometry measurements of p-p38–MAPK
ymeasurements of cleaved caspase-9, cleaved caspase-3 and phosphorylated Pak1 expres-
and slug expressions inprostate tumor xenografts (left) and bar graph representing optical
5 and **P b 0.01. Data presented as mean ± SEM.
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Whole-cell or prostate tissue lysates were prepared using lysis buff-
er [50mMTris–HCl, pH 7.4, 1% Triton X-100, 150mMNaCl, 1mMEDTA,
2 mM Na3VO4, and 1× complete protease inhibitors (Roche Applied
Science, Indianapolis, IN)]. The protein concentration was measured
by the DL protein assay (Bio-Rad Laboratories, Hercules, and CA).
Western blot analyses were performed as described previously [11].
Densitometry was done using NIH ImageJ software.
2.4. Rac1 activity assay
Rac1 activation assay was performed using a kit from Cytoskeleton
(Denver, CO) as described before [45]. Brieﬂy, PC3 and DU145 cells
were treated with TGFβ1 (5 ng/ml) for 24 h and lysates were prepared.
1 mg of cell lysates was mixed in Rac lysis buffer with Glutathione–
Sepharose 4B beads conjugated with the P21-binding domain (PBD)
of Pak1 fused to Glutathione S-transferase. This was followed with
incubation and shaking at 4 °C for 1 h. After that beads were collected
through centrifugation and washed 3 times using washing buffer
containing 1× protease inhibitor (Roche Applied Science, IN), and three
times with 1× PBS. Proteins were eluted by boiling beads in 2× Laemmli
sample buffer (BioRad, Hercules, CA) for 5 min, separated on a 12% SDS–
polyacrylamide gel and the amount of activated Rac1 was determined
using primary antibody against Rac1 from Sigma-Aldrich (St Louis, MO).
2.5. Cell scattering assay
PC3 and DU145 cells were seeded at a low density andwere allowed
to grow to form small colonies. After the formation of small scatteredFig. 2. Treatmentwith IPA 3 results in the growth inhibition of prostate tumor xenografts. A. Pan
pictures of tumor xenograft fromDMSOor IPA 3 (5mg/kg) treatments groups onDay 24 (n=4–
IPA 3 (5 mg/kg) collected on Day 24. D. Bar graph representing mice body weight on the datecolonies, we replaced the DMEM/HG medium with fresh medium
containing 5% FBS and cells were treated with TGFβ1 (5 ng/ml)
after IPA 3 (15 μM) treatment for 1 h prior to the addition of
TGFβ1. This treatment was done daily for 3 days. Cell scattering
images were taken using phase contrast as well as ﬂuorescence mi-
croscopes and the bright ﬁeld images were used for quantitative
analysis after selecting 4 images each per experimental group to
determine the area occupied by the cells per ﬁeld using NIH Image
J software.
2.6. Cell migration assay
Cellmigration assay (Scratch Assay)was performed as described be-
fore [11]. Brieﬂy, Both PC3 and DU145 cells were grown on 12-well
plates to reach conﬂuence and then scratches were made in the
cell monolayers using 1 ml pipette tips followed by treatments with
TGFβ1(5 ng/ml) alone, TGFβ1 after 1 h of IPA 3 treatment or IPA 3
alone (15 μM). Control cells were incubated in DMEM including 5%
serum alone. Images of scratches were taken at time zero and 72 h. The
rate of migration was measured using the equation ([1-T72/T0] × 100),
where T72 is the area at the end point (72 h) and T0 is the area at the
start time (0 h).
2.7. Transwell invasion assay
24 Transwell permeable plates support 8.0 μm polycarbonate mem-
brane coated with Matrigel® obtained from Corning (Tewksbury, MA)
were used. Brieﬂy cells were seeded in 6 well plates and treated with
either TGFβ1 (5 ng/ml), IPA 3 alone (15 μM), or combined treatment
of both every day for total of 72 h. Following this, cells were detachedel showing tumor volumemeasurements fromDay 0 to Day 24 (left) andB. Representative
5) (right). C. Bar graph showingweights of tumors frommice treatedwith either DMSO or
of tumor collection. (n= 4–5). *p b 0.05 and **P b 0.01. Data presented as mean ± SEM.
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and 5000 cells were plated on the upper chamber of the transwell
plates. Upper chambers were ﬁlled with serum free medium and
lower chambers were ﬁlled with DMEM/HG medium containing
20% FBS as a chemo-attractant. Cells that invaded the Matrigel®
and reached the bottom layers of the top chambers after 24 h of incu-
bation were ﬁxed using 3.7% paraformaldehyde then stained with
0.5% crystal violet solution. The cells were counted manually using
the inverted microscope and the average was calculated from 4
random images.2.8. TUNEL assay
The TUNEL assay for in situ detection of apoptosis was performed
using the ApopTag® Fluorescein in Situ Apoptosis detection kit
(Millipore, MA) as previously [4,10]. Fixed frozen sections from pros-
tate tumor xenografts were permeabilized in ethanol:acetic acid
[2:1] mixture and labeled with ﬂuorescein 12-dUTP using terminal
deoxynucleotidyl transferase. Nuclei were counterstained with
DAPI. Tissue sections were analyzed for apoptotic cells with localized
green ﬂuorescence using an inverted ﬂuorescence microscope (Zeiss
Axiovert100M, Carl Zeiss, Germany).Fig. 3. TGFβ1 treatment enhances Rac1-mediated Pak1 activation and expression ofmesenchym
Rac1 (Rac1-GTP) bands after one time treatments with TGFβ1 (5 ng/ml) or control vehicle in PC
expressions normalized to β-actin after treatment of PC3 and DU145 cells with or without TGF
total Pak1, P-smad2/3, and T-Smad after one time treatmentswith TGFβ1 (5 ng/ml) or vehicle f
analysis P-PAK1/2 normalized to total Pak1 after treatmentwith TGFβ1 (5 ng/ml) or PBS for 1, 3
blot images of EMT marker expression and active Rac1-GTP in PC3 cells after being subjected
densitometry measurements for Rac1-GTP and TGFβ expression levels in PC3 cells after 48 h p
of Snail and N-cadherin expressions, respectively, in PC3 cells 48 h post-transfection with Ad-G2.9. Phalloidin staining
Phalloidin immunoﬂuorescence staining of the cells was performed
as described previously [11]. Brieﬂy, PC3 or DU145 cells were plated
on cell culture chamber slides (Fisher Scientiﬁc, Pittsburgh, PA) at low
density were subjected to treatment with TGFβ1 (5 ng/ml) every day.
After 72 h, cells were washed 2 times with 1× PBS and ﬁxed with 1%
paraformaldehyde in PBS. Cells were permeabilized using 0.1% Triton
X-100 in PBS. The nonspeciﬁc staining was blocked with 2% BSA for
1 h at room temperature. Slides were incubated with Alexa Fluor 555-
labeled phalloidin for 20 min at room temperature and washed 4
times with 1× PBS. The slides were mounted with Vectashield (Vector
Laboratories), and the images were taken by an inverted ﬂuorescence
microscope (Zeiss Axiovert100M, Carl Zeiss, Germany).2.10. In vivo prostate tumor xenograft
All animal procedures listed in this article were performed as per the
protocol approved by the Institutional Animal Care and Use Committee
at the Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
(protocol # 12-06-049). PC3 cells were grown to reach 50% conﬂuence
and subjected to Adenoviral transfection to overexpress TGFβ1; controlalmarkers (Snail andN-cadherin) in prostate cancer cells. A.Western blot images of active
3 and DU145 cells (left) and bar graphs showing band densitometry analysis of Rac1-GTP
β1 (5 ng/ml) for 24 h (right) (n= 4). B. Representative Western blot images of P-PAK1/2,
or 1, 3, 6, 12, 24 and 48 h in PC3 and DU145 cells. C. Bar graphs showing band densitometry
, 6, 12, 24 and 48 h in PC3 andDU145 cells, respectively (n=4). D. RepresentativeWestern
to infection with either control Ad-GFP or Ad-TGFβ1. E. Bar graphs representing optical
ost transfection (n= 4). F. Bar graphs representing optical densitometry measurements
FP or Ad-TGFβ1 (n= 4). *p b 0.05 and **P b 0.01. Data presented as mean ± SEM.
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transfection, cells were collected and suspended in sterile normal sa-
line. Cell suspension (3 million cells//mouse) was injected subcuta-
neously (SC) in 6–8-week-old male nude mice (Athymic nude
mice; Harlan, Indianapolis, IN). Tumor diameters were measured
with digital calipers on day 7, 14, 21, and 28, and the tumor volume
in mm3 was calculated by the modiﬁed ellipsoidal formula (Tumor
volume = ½[length × width2]) [7]. Mice were euthanized on day 28
and tumors were dissected, weighed, and snap-frozen for further
western blot and immunohistochemistry analysis.2.11. Statistical analysis
All data are presented as means ± S.E.M. to determine signiﬁcant
differences between treatments and control values. We have used
either one way ANOVA for groups of 3 or more. Student's t test was
used for studies including 2 independent groups. Statistical analysis
was performed using GraphPad Prism version 6 software.Fig. 4. TGFβ1 enhances Snail and N-cadherin expression, and EMT in prostate cancer cells. A
formation (phalloidin staining) in PC3 and DU145 cells (×40 magniﬁcation) and phase-contra
magniﬁcation). B. Bar graphs showing quantiﬁcation of the cell scattering data in PC3 (left) and
8, N-cadherin, Vimentin, Snail, and Slug after one time treatmentwith TGFβ1 (5 ng/ml) or no tr
densitometry analysis of N-cadherin expression in PC3 cells, after one time treatment with TGF
graph showing optical band densitometry analysis of N-cadherin expression in DU145 cells, aft
malized to β-actin (n=4). F. Bar graph showing optical band densitometry analysis of Snail ex
and 72hnormalized toβ-actin (n=4). G. Bar graph showing optical banddensitometry analysi
for 12, 24, 48, and 72 h normalized to β-actin (n= 4). *p b 0.05 and **P b 0.01. Data presented3. Results
3.1. TGFβ1 overexpression or Pak1 inhibition results in reduced prostate
tumor growth
Wehave previously reported that TGFβ1 induces apoptosis inmeta-
static prostate cancer cells via P38-MAPK pathway leading to activation
of caspases [3]. We also showed that Pak1 inhibition leads to increased
expression of TGFβ in prostate cancer cells, once again correlating with
impaired prostate tumor xenograft growth and transendothelial migra-
tion [11]. This suggested the existence of a feedback loop mechanism
between PAK1 and TGFβ1 in prostate cancer. We ﬁrst examined the
effect of TGFβ1 overexpression in PC3 cells on tumor growth in athymic
nudemice, and determined whether TGFβ1 overexpression will lead to
inhibition of Pak1 expression or activity. Our results demonstrated that
TGFβ1 overexpression inhibits prostate tumor growth and reduces
tumor volume and weight, as compared to the control group (PC3
cells transfectedwith adenovirus encoding GFP) (Fig. 1A and B; Supple-
mental Fig. 1A and B). Decreased prostate tumor growthwas associated. Representative images showing the effect of TGFβ1 (5 ng/ml for 3 days) on stress ﬁber
st images showing the effect of TGFβ1 (5 ng/ml) on cell scattering in both cell lines (×20
DU145 (right) cells (n=4). C. RepresentativeWestern blot images of E-cadherin, keratin
eatment for 12, 24, 48, and 72 h in PC3 and DU145 cells. D. Bar graph showing optical band
β1 (5 ng/ml) or no treatment for 12, 24, 48, and 72 h normalized to β-actin (n=4). E. Bar
er one time treatment with TGFβ1 (5 ng/ml) or no treatment for 12, 24, 48, and 72 h nor-
pression in PC3 cells, after treatments with TGFβ1 (5 ng/ml) or no treatment for 12, 24, 48,
s of Snail expression inDU145 cells, after treatmentswith TGFβ1 (5 ng/ml) or no treatment
as mean ± SEM.
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staining assay (Fig. 1D). Our results also indicated that p-P38 MAPK
phosphorylation, and cleaved caspase-3 and cleaved caspase-9 levels
were elevated in the TGFβ1 overexpressing PC3 cells compared to con-
trol group (Fig. 1E and F). Intriguingly, we observed increased Pak1
phosphorylation (Fig. 1E) and increased expression of Snail (Fig. 1G)
with TGFβ1 overexpression in prostate tumor xenografts. Next, we
sought to determine if pharmacological inhibition of Pak1 using a
selective inhibitor IPA 3 will enhance or inhibit prostate tumor growth.
Our data indicated that treatment with IPA 3 signiﬁcantly inhibited the
growth of prostate tumor xenografts in athymic nude mice (Fig. 2A–C).
Either of the TGFβ or IPA 3 did not have any effect on mice body weight
(Fig. 1C and 2D, respectively). Taken together our results indicated that
although both TGFβ1 stimuli and Pak1 inhibition lead to the inhibition
of prostate tumor growth in vivo, TGFβ1 stimuli results in increased
phosphorylation of Pak1, thus suggesting a complex relationship be-
tween TGFβ1 and Pak1-mediated cytoskeletal remodeling in prostate
cancer.
3.2. TGFβ1 treatment enhances Rac1-mediated Pak1 activation in prostate
cancer cells
Our previous study has demonstrated the importance of 14-3-3,
Rac1 and Pak1 in prostate cancer cell cytoskeletal remodeling, motility
and micrometastasis [10,11], suggesting that Pak1 activity may be nec-
essary for the acquisition of metastatic potential. The fact that TGFβ1
stimuli enhanced Pak1 phosphorylation despite inducing apoptosis in
prostate tumor xenografts further complicated our view on the role ofFig. 5. Pharmacological inhibition of Pak1with IPA 3 inhibits TGFβ1-induced EMT-associatedmo
images of PC3 and DU145 cell scattering following 72 h treatments with TGFβ1 (5 ng/ml), or IP
DU145 cells as treated above (n=4). C and D. Representative images and bar graph of PC3 cell
(n= 4). E and F. Representative images and bar graph of DU145 cell migration following 48 h
**P b 0.01. Data presented as mean ± SEM.TGFβ1 and Pak1 on prostate cancer cell function. Hence we decided to
further characterize the effect of TGFβ1 stimuli on the activation of
Rac-Pak1 pathway in prostate cancer cells. Our analysis of PC3 and
DU145 cells indicated that treatment with TGFβ1 induced Rac1 activa-
tion (Fig. 3A) associatedwith a signiﬁcant and time-dependent increase
in Pak1 (Ser199/204 and PAK2 Ser192/197) phosphorylation (Fig. 3B and C).
Our results thus conﬁrmed that although TGFβ1 induces apoptosis,
TGFβ1 treatment in prostate cancer leads to activation of Rac1–Pak1
pathway.
3.3. TGFβ1 augments EMT in metastatic prostate cancer cells
Initial clues on the possible role of TGFβ1 on EMT came from our
ﬁnding of increased Pak1 phosphorylation in the tumor lysates with
TGFβ1 overexpression. Based on this, our further analysis of tumor cell
lysates and PC3 cells overexpressing TGFβ1 revealed that TGFβ1 treat-
ment induces a signiﬁcant increase in the expression of EMT markers,
particularly Snail and N-cadherin (Fig. 3D–F). We then determined the
direct effect of TGFβ1 on prostate cancer (PC3 and DU145) cell mor-
phology. Based on the results of the phalloidin staining and cell scatter-
ing assays, TGFβ1 treatment (5 ng/ml) once every 24 h for a total of 72 h
induced strong morphological changes (spindle-like morphology) and
cell scattering (more gaps between the cells and increased area occu-
pied by the colonies) (Fig. 4A and B), which are generally associated
with the EMT. In line with these morphological changes, we sought to
determine the effect of TGFβ1 on EMTmarkers (repression of epithelial
proteins accompanied with induction of mesenchymal markers pro-
teins). TGFβ1 (5 ng/ml) treatment was associated with suppression ofrphological changes, cell scattering, andmotility in prostate cancer cells. A. Representative
A 3 (15 μM), or a combination. B. Bar graph showing quantiﬁcation of the cell scattering in
migration following 48 h treatments of TGFβ1 (5 ng/ml), IPA 3 (15 μM), or a combination
treatments of TGFβ1 (5 ng/ml), IPA 3 (15 μM), or a combination (n= 4). *p b 0.05 and
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TGFβ1 decreased the expression of E-cadherin in DU145 cells, it in-
creased the E-cadherin expression in PC3 cells. However, the increase
in expression of other mesenchymal markers such as N-cadherin,
Snail, vimentin and slugwith TGFβ1 treatment was consistent between
the PC3 and DU145 cells (Fig. 4C–G and Supplemental Fig. 1). Taken to-
gether, our results on the morphological and EMT marker expression
proﬁle strongly suggested that treatment with TGFβ1 induces EMT in
prostate cancer cells.
3.4. Pharmacological inhibition of Pak1 reverses EMT-associated morpho-
logical changes, cell scattering, and motility in prostate cancer cells
Since Pak1-mediated cytoskeletal assembly is essential for prostate
cancer cell motility, we assumed that Pak1 activation induced by
TGFβ1 may be necessary for the promotion of EMT. To conﬁrm this,
we treated both PC3 and DU145 cells with a selective Pak1 inhibitor
(IPA 3), which works through covalent binding to the Pak1 regulatory
domain and preventing the binding of the upstream activators (Rac1/
cdc42) [49]. Cells treatedwith IPA 3were associatedwith signiﬁcant in-
hibition of TGFβ1-mediated cell scattering and morphological changes
similar to mesenchymal cells (Fig. 5A and B). We next examined the
role of Pak1 in TGFβ1-mediated prostate cancer migration. We subject-
ed both PC3 and DU145 cells to cell migration (scratch recovery) after
treatment with TGFβ1 (5 ng/ml), IPA 3 (15 μM), or both. Treatment
with IPA 3 resulted in signiﬁcant inhibition of TGFβ1-mediated PC3
(Fig. 5C and D) and DU145 (Fig. 5E and F) cell migration. Our data indi-
cated that targeting Pak1 pathway may inhibit prostate cancer EMT by
TGFβ1 stimuli.Fig. 6. IPA 3, selective Pak1 inhibitor inhibits TGFβ1-mediated EMT in prostate cancer cells. A, R
treatments with TGFβ1 (5 ng/ml), IPA 3 (15 μM), or combination, with treatments repeated ev
Snail and N-cadherin expressions respectively in PC3 cells following 72 h treatments with TGFβ
of EMT markers expression in DU145 cells following 72 h treatments with TGFβ1 (5 ng/ml),
mesenchymal markers, Snail and N-Cadherin expressions respectively in DU145 cells follo
*p b 0.05. Data presented as mean ± SEM.3.5. Treatment with IPA 3 reverses EMT marker expression and invasion
Since treatmentwith IPA 3 reversed TGFβ1-mediatedmorphological
changes in prostate cancer cells, we next determined if inhibition of
Pak1 expression has any effect on the expression of EMT markers. Our
data revealed that IPA 3 signiﬁcantly suppresses TGFβ1-mediated
increase in the expression of mesenchymal markers N-cadherin
and Snail in PC3 (Fig. 6A–C) andDU145 (Fig. 6D–F) cells. To further con-
ﬁrm our data, we used Pak1 siRNA to determine if these effects mediat-
ed by IPA 3 treatments were selectively dependent on Pak1 activity
inhibition. Cells were transfected with either control siRNA or Pak1
siRNA for 48 h then treated with either TGFβ1 (5 ng/ml) or vehicle
(sterile PBS) for additional 24 h. siRNA-mediated Pak1 knockdown
blunted TGFβ1-mediated increase in EMT markers N-cadherin and
Snail in PC3 cells (Fig. 7A–C). Our results thus demonstrate that selec-
tive inhibition of Pak1 activity leads to reversion of TGFβ1-mediated
EMT switch.
3.6. TGFβ1-induced Pak1 activation is dependent on non-canonical TRAF6-
mediated pathway
Since TGFβ1 activates both canonical Smad-dependent [23] and
non-canonical TRAF4/6-mediated pathway [16,53], we next inves-
tigated the pathway responsible for the TGFβ1-induced Pak1 acti-
vation in prostate cancer cells. Our analysis indicated that SiRNA-
mediated knockdown of Smad-2 in PC3 cells had no signiﬁcant
effect on the phosphorylation of Pak1 (Fig. 7D). Interestingly,
SiRNA-mediated knockdown of TRAF6 in PC3 cells resulted in a sig-
niﬁcant reduction in the levels of phosphorylated Pak1 (Fig. 7E),epresentative Western blot images of EMT marker expression in PC3 cells following 72 h
ery 24 h. B and C. Bar graph representing optical densitometry for mesenchymal markers,
1 (5 ng/ml), IPA 3 (15 μM), or combination (n=3). D, RepresentativeWestern blot images
IPA 3 (15 μM), or combination. E and F. Bar graph representing optical densitometry of
wing 72 h treatments with TGFβ1 (5 ng/ml), IPA 3 (15 μM), or combination (n = 3).
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in PC3 cells (Fig. 7F). Our results indicate that TGFβ1-induced Pak1
activation involved a Smad2-independent, TRAF6-dependent non
canonical pathway.
Acquisition of mesenchymal morphology in EMT has been linked to
cancer cell invasion [25]. Hence, we determined whether inhibition of
Pak1 will affect TGFβ1-induced invasion of prostate cancer cells. To do
this, we employed both pharmacological inhibition using IPA 3 and
siRNA-mediated knockdown of Pak1 and then subjected these cells for
a Matrigel®-based Boyden chamber invasion assay in vitro. Both PC3
and DU145 cells were subjected to invasion assay usingMatrigel® coat-
ed transwells after the cells were treated with TGFβ1 (5 ng/ml), IPA 3
(15 μM), or a combination of TGFβ1and IPA 3. Alternatively, PC3 and
DU145 cells with siRNA-mediated Pak1 gene knockdown were also
subjected for TGFβ1 treatment and invasion assay. Our data revealed
that TGFβ1 treatment is associated with an increase in PC3 (Fig. 8A, C
and E) and DU145 (Fig. 8B, D and F) prostate cancer cell invasion, and
these effects were signiﬁcantly abolished by suppression Pak1 activity
using either IPA 3 or siRNA mediated gene silencing (Fig. 8). Together,
our data demonstrate that Pak1 activation upon TGFβ1 stimuli via
TRAF6-mediated non-canonical pathway is important for prostate
cancer EMT.Fig. 7. Selective Pak1 knockdown in PC3 cells inhibits EMTmarker expression induced by TGFβ1
marker expression in PC3 cells after being subjected to either control siRNA or Pak1 siRNA for 4
representing optical densitometry measurements for mesenchymal marker expression (N-cad
(n= 3). D. Representative Western blot images and bar graph showing changes in the phosp
treatment with or without TGFβ1 (5 ng/ml) for 24 h in PC3 cells, compared to Si-Control (n=
measurements for phosphorylated Pak1 in Control-siRNA or TRAF6 SiRNA transfected PC3 ce
Pak1 phosphorylation in PC3 cells with Pak1 knockdown (n= 3).*p b 0.05 and **P b 0.01. Dat4. Discussion
Previous studies have demonstrated the central role of TGFβ1 in
EMT as characterized by the reduced epithelial marker expression, in-
creased mesenchymal marker expression, loss of cell–cell contacts and
increased cell motility/invasion leading to cancer metastasis [31,48].
However, the mechanism by which TGFβ1 promotes EMT is still not
clear. We have previously demonstrated that 14-3-3ζ-Rac1 signaling
pathway, an upstream modulator of Group I Paks including Pak1 is
necessary for prostate cancer cell (LNCaP and PC3) motility and
transendothelial migration [10]. We also demonstrated that P21-
activated kinase 1 (Pak1) is highly expressed inmetastatic prostate can-
cer cells (PC3, LNCaP C4-2 and VCaP) compared to the non-metastatic
cells (LNCaP) and that Pak1 expression is highly elevated in metastatic
prostate cancer tissues compared to normal and benign prostatic hyper-
plasia tissues. Interestingly, our previous study also indicated that Pak1
enhances prostate tumor xenograft growth via down regulating TGFβ
expression [11]. Literature supports that Pak1 signaling is essential for
EMT process in various epithelial cells [15,20,41]. However, the role of
Pak1 in cancer EMT, more particularly in the prostate, where Pak1 is
expressed only in cancer is not clear. Hence, in the current study, we fo-
cused on characterizing the link between the TGFβ1 and Pak1 intreatment involving TRAF6 pathway. A. RepresentativeWestern blot images showing EMT
8 h followed by treatment with or without TGFβ1 (5 ng/ml) for 24 h. B and C. Bar graphs
herin and Snail, respectively) in either Control-siRNA or Pak1 siRNA transfected PC3 cells
horylation of Pak1 with the Si-RNA-mediated knockdown of Smad2 for 48 h followed by
3). E. Representative Western blot images and bar graph showing optical densitometry
lls (n= 3). F. Representative Western blot image and bar graph showing changes in the
a presented as mean ± SEM.
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Pak1 activation by TGFβ1 in the promotion of EMT.
In various cancers such as breast [5,39], lung [38] and renal cell car-
cinoma [32], group I Paks, Pak1 in particular, have been implicated in
the promotion of oncogenic transformation, tumor progression andme-
tastasis [18,36]. Research on the role of group I Paks in prostate cancer
has been hampered due to the reason that group I Paks are not abun-
dantly expressed in the normal prostate gland, and is absent in prostatic
epithelial cells [11]. Instead, prostate gland expresses high levels of
group II Paks, Pak4 and Pak6 [1,33,40]. Intriguingly, it was not clear
what mediated cytoskeletal changes in prostate cancer cells, which is
essential for the acquisition of invasive andmetastatic potential by pros-
tate cancer cells. It is known that group II Paks has no Rac1 binding PBD
region, and that regulation of group II Pak activity is independent of
Rac1 and cdc42 activation [18]. This suggested that although group I
Paks are expressed in low amounts in the prostate gland, its enhanced
expression and activation may be necessary for the promotion of pros-
tate cancer EMT by TGFβ1.
Although an association between group I Paks and invasion was not
established in prostate cancer cells, there were reports supporting pos-
sibility of such an association [8]. Our follow-up study identiﬁed that al-
though Pak1 is not highly expressed in low grade prostate cancer cell
lines and in normal human prostate or benign prostatic hyperplasia tis-
sue samples; its expressionwas higher inmetastasized tissues including
lymph node and lungs [11]. Increased expression of Pak1 was alsoTGFβ1
TGFβ1+ IPA3 IPA3
Control
Si-Control Si-Control+TGFβ1
Si-Pak1 Si-Pak1+TGFβ1
PC
3 
Ce
lls
*
N.S
** **
PC3
PC3
A
C D E
Fig. 8. IPA-3, selective Pak1 inhibitor or Pak1 knockdown prevents TGFβ1-mediated prostate c
of PC3 cells subjected to either IPA 3 treatment or Pak1 knockdown. B, Representative images
treatment or Pak1 knockdown. C and D. Bar graphs showing PC3 cell invasion (cells/ﬁeld)
DU145 cell invasion (cells/ﬁeld) after subjected to either IPA 3 treatment or Pak1 knockdownobserved in aggressive human prostate cancer cell lines [11]. We also
conﬁrmed that inhibition of Pak1 via shRNA-mediated gene silencing
leads to growth inhibition of PC3 tumor xenograft in nudemice [11]. In-
terestingly, this was accompanied with an increase in the expression of
TGFβ in the PC3 tumor xenografts, thus suggesting that there is a likely
existence of a Pak1–TGFβ signaling loop thus promoting tumor progres-
sion and invasion.
Since TGFβ is a well-known tumor suppressor in prostate cancer
cells [3,6,13,51], we assumed that increased TGFβ expression due to
Pak1 inhibition may have an effect on the inhibition of tumor growth
in addition to the effect of Pak1 inhibition on cytoskeletal remodeling
in prostate cancer cells. However, recent literature also indicates that
TGFβ switches its role to promote metastasis in advanced prostate
tumors [25,47]. This complicated our view on how TGFβ and Pak1
may be associated in the promotion of prostate cancer cell invasion.
Our results indicated that TGFβ1 overexpression in PC3 prostate
tumor xenografts induced apoptosis mainly through the activation of
stress-activated p38–MAPK pathway, thus conﬁrming the predominant
role of TGFβ1 as a tumor suppressor [3,30,35,46,51]. Surprisingly, TGFβ1
overexpression resulted in signiﬁcantly increased active Rac1 and phos-
phorylated Pak1/2 accompanied by increased expression of a mesen-
chymal markers Snail and N-Cadherin. These results suggested that
while TGFβ1 acts predominantly as a prostate tumor growth suppressor
via inducing apoptosis, it concurrently induced phenotypic switching
and expression of mesenchymal markers in a subgroup of prostateSi-Control
Si-Pak1
TGFβ1
TGFβ1+ IPA3 IPA3
Control
Si-Control+TGFβ1
Si-Pak1+TGFβ1
D
U1
45
 C
el
ls
N.S
*** **
DU145
DU145
B
F
ancer cells invasion. A. Representative images of transwell plates following invasion assay
of transwell plates following invasion assay of DU145 cells after subjected to either IPA 3
after either IPA 3 treatment or Pak1 knockdown (n = 4). E and F, Bar graphs showing
(n= 4). *p b 0.05 and **P b 0.01. Data presented as mean ± SEM.
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resulted in EMT, characterized by morphological changes, increased
cell scattering, loss of cell–cell contacts, loss in epithelial markers, and
acquisition of mesenchymal markers. These results were in agreement
with the literature that despite being a tumor suppressor early on,
prolonged TGFβ1 stimuli can promote EMT and enhance invasiveness
of the prostate cancer cells [31,48].
It is known that both canonical Smad-dependent and non-canonical
pathways are necessary for the TGFβ-induced effects on epithelial cells
[23,24]. Although not proven, scientists argue that while canonical
pathway is responsible for the tumor suppressive effect of TGFβ, the
EMT-promoting effects of TGFβ are dependent on the activation of
non-canonical pathways leading to activation of small Rho-GTPases
such as Rac1 and cdc42 [21]. Our results showed that TGFβ1-induced
Pak1 activation is independent of canonical Smad2–pathway and is
dependent on the non-canonical TRAF6 pathway.
Although we established that Rac1 and Pak1 activities are essential
for cytoskeletal remodeling in prostate cancer cells, there are no reports
indicating the potential role of Rac1–Pak1 pathway in TGFβ1-induced
EMT in prostate cancer cells. Our study also revealed for the ﬁrst time
that prolonged treatment of prostate cancer cells with TGFβ1 results
in increased activation of Rac1 and Pak1. Pak1 deﬁcient PC3 cells were
resistant to TGFβ1-promoted EMT and invasion of prostate cancer
cells. IPA 3, a selective allosteric Pak1 inhibitor was able to reverse
TGFβ1-associated EMT suggesting the indispensable role of “Rac1–
Pak1” axis in TGFβ1-mediated cytoskeletal remodeling and EMT. Pak1
deﬁcient PC3 cells were resistant to TGFβ1-promoted EMT and invasion
of prostate cancer cells. In conclusion, we show for the ﬁrst time that
TGFβ1 induces cytoskeletal remodeling, EMT, invasion and metastasis
via regulation of “Rac1–Pak1 axis”. These results suggest that targeting
this axis could be a potential treatment target for the advanced-stage
prostate cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.02.023.
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